Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But H...
Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42
About this item
Full title
Author / Creator
Publisher
Switzerland: Frontiers Research Foundation
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: Frontiers Research Foundation
Subjects
More information
Scope and Contents
Contents
Amyloid beta 1-43 (Aβ43) may be a useful additional biomarker for diagnosing Alzheimer's disease (AD). We have investigated cerebrospinal fluid (CSF) levels of Aβ43 in patients with early-onset AD in contrast to levels in late-onset AD. For comparison, in addition to the 'core' biomarkers, several other analytes were also determined [YKL-40, neurof...
Alternative Titles
Full title
Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_749298b21fd8489083bbf62d1206dafd
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_749298b21fd8489083bbf62d1206dafd
Other Identifiers
ISSN
1663-4365
E-ISSN
1663-4365
DOI
10.3389/fnagi.2017.00210
